Evidence map›Paper›PMID 32210100›Full record

ArticleInternational journal of molecular sciences2020

Type 1 FSHD with 6-10 Repeated Units: Factors Underlying Severity in Index Cases and Disease Penetrance in Their Relatives Attention.

Emmanuelle Salort-Campana, Farzad Fatehi, Sadia Beloribi-Djefaflia, Stéphane Roche, Karine Nguyen, Rafaelle Bernard, Pascal Cintas, Guilhem Solé, Françoise Bouhour, Elisabeth Ollagnon and 6 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 3 countries.

Emmanuelle Salort-CampanaReference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 264 rue Saint-Pierre, Cedex 05 13385 Marseille, France.
Farzad FatehiReference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 264 rue Saint-Pierre, Cedex 05 13385 Marseille, France.ORCID 0000-0002-6774-7825
Sadia Beloribi-DjefafliaReference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 264 rue Saint-Pierre, Cedex 05 13385 Marseille, France.
Stéphane RocheMedical Genetics, Aix Marseille Université-Inserm UMR_1251, 13005 Marseille, France.
Karine NguyenMedical Genetics, Aix Marseille Université-Inserm UMR_1251, 13005 Marseille, France.
Rafaelle BernardMedical Genetics, Aix Marseille Université-Inserm UMR_1251, 13005 Marseille, France.
Pascal CintasService de Neurologie et d'explorations fonctionnelles, Centre Hospitalier Universitaire de Toulouse, 31000 Toulouse, France.
Guilhem SoléReference Center of Neuromuscular Disorders AOC, Bordeaux University Hospitals, 33000 Bordeaux, France.ORCID 0000-0001-9599-6573
Françoise BouhourElectroneuromyography and Neuromuscular Department, GHE Neurologic Hospital, Cedex 69677 Lyon-Bron, France.
Elisabeth OllagnonNeurogenetic Department, GHN Croix-Rousse Hospital, 69004 Lyon, France.
Sabrina SacconiNeuromuscular Disease Specialized Center, Nice University Hospital, 06000 Nice, France.
Andoni Echaniz-LagunaNeurology Department, APHP, CHU de Bicêtre, 78 rue du Général Leclerc, Cedex 94276 Le Kremlin-Bicêtre, France.
Thierry KuntzerNerve-Muscle Unit, Department of Clinical Neurosciences, Lausanne University, Hospital (CHUV), Lausanne 1002, Switzerland.ORCID 0000-0002-7788-1673
Nicolas LevyMedical Genetics, Aix Marseille Université-Inserm UMR_1251, 13005 Marseille, France.
Frédérique MagdinierMedical Genetics, Aix Marseille Université-Inserm UMR_1251, 13005 Marseille, France.ORCID 0000-0002-0159-9559
Shahram AttarianReference Center of Neuromuscular disorders and ALS, Timone University Hospital, AP-HM, 264 rue Saint-Pierre, Cedex 05 13385 Marseille, France.
Inserm · FRBicêtre Hospital · FRCentre Hospitalier Universitaire de Nice · FRCentre Hospitalier Universitaire de Toulouse · FRHôpital de la Croix-Rousse · FRTehran University of Medical Sciences · IRUniversité de Bordeaux · FRUniversity Hospital of Lausanne · CH

Funding

Association Française contre les Myopathies 10906
6 · The paper itself

Abstract

Molecular defects in type 1 facioscapulohumeral muscular dystrophy (FSHD) are caused by a heterozygous contraction of the D4Z4 repeat array from 1 to 10 repeat units (RUs) on 4q35. This study compared (1) the phenotype and severity of FSHD1 between patients carrying 6-8 vs. 9-10 RUs, (2) the amount of methylation in different D4Z4 regions between patients with FSHD1 with different clinical severity scores (CSS). This cross-sectional multicenter study was conducted to measure functional scales and for genetic analysis. Patients were classified into two categories according to RUs: Group 1, 6-8; Group 2, 9-10. Methylation analysis was performed in 27 patients. A total of 99 carriers of a contracted D4Z4 array were examined. No significant correlations between RUs and CSS (r = 0.04,

Indexed as

Genetic Association StudiesGenetic Predisposition to DiseaseRepetitive Sequences, Nucleic AcidAdultAllelesAttentionCross-Sectional StudiesDNA MethylationFemaleGenotypeHumansMaleMiddle AgedMuscular Dystrophy, FacioscapulohumeralPenetrancePhenotypeassociationcorrelationFacioscapulohumeral muscular dystrophyFSHDgenotypemethylationphenotype

Identifiers

PMID32210100
PMCPMC7139460
OpenAlexW3012819374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.